^
    1m
    Metastatic Unfunctional Pancreatic Neuroendocrine Tumor in Lynch Syndrome. (PubMed, Clin Case Rep)
    Liver lesions shrank after treatment with octreotide and Lutetium-177 vipivotide tetraxetan...The role of microsatellite instability (MSI) as a screening marker, and personalized treatment approaches like immunotherapy for dMMR tumors. Understanding these correlations may assist in early discovery, surveillance, and customized treatment for patients dealing with LS-associated malignancies.
    Journal • IO biomarker
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    1m
    IUNU-PC-123: 177Lu-PSMA-617 Combined With Darolutamide in Neoadjuvant Treatment of High-risk Localized Prostate Cancer: a Prospective, Single-arm, Multi-center Clinical Trial (clinicaltrials.gov)
    P4, N=20, Not yet recruiting, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
    New P4 trial
    |
    Nubeqa (darolutamide) • Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    1m
    A Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan (clinicaltrials.gov)
    P=N/A, N=1067, Not yet recruiting, Novartis Pharmaceuticals
    New trial • Real-world evidence
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    1m
    PROSPECTOR: Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer (clinicaltrials.gov)
    P1/2, N=152, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting
    Enrollment open
    |
    FOLH1 positive
    |
    docetaxel • AZD9574 • FPI-2265
    1m
    Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLT (clinicaltrials.gov)
    P1, N=33, Active, not recruiting, Novartis Pharmaceuticals | Phase classification: P1/2 --> P1 | Trial completion date: Nov 2029 --> Mar 2031 | Trial primary completion date: Nov 2026 --> Mar 2031
    Phase classification • Trial completion date • Trial primary completion date
    |
    FOLH1 positive
    2ms
    PSMA-High: EBRT/ PSMA617/ ADT vs. EBRT/ ADT (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Apr 2033 --> Jul 2033 | Initiation date: Apr 2026 --> Jul 2026 | Trial primary completion date: Apr 2032 --> Jul 2032
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    2ms
    ENZA-p: Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer (clinicaltrials.gov)
    P2, N=162, Active, not recruiting, Australian and New Zealand Urogenital and Prostate Cancer Trials Group | Trial completion date: Jan 2025 --> Dec 2026
    Trial completion date
    |
    enzalutamide • Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    2ms
    Clinical Evaluation of 177Lu-PSMA-VG01 Injection in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer （mCRPC） (clinicaltrials.gov)
    P1, N=10, Recruiting, VitsGen Therapeutics Inc.
    New P1 trial
    2ms
    Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial (clinicaltrials.gov)
    P2, N=202, Not yet recruiting, Mayo Clinic
    New P2 trial
    |
    abiraterone acetate • Eligard (leuprolide acetate) • Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • Viadur (leuprorelin implant) • Yonsa (abiraterone acetate)
    2ms
    Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial (clinicaltrials.gov)
    P3, N=1524, Recruiting, Alliance for Clinical Trials in Oncology | Not yet recruiting --> Recruiting | Initiation date: Oct 2025 --> Mar 2026
    Enrollment open • Trial initiation date
    |
    FOLH1 positive
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    2ms
    Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function (clinicaltrials.gov)
    P2, N=23, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting | Trial completion date: Jun 2026 --> Dec 2026 | Trial primary completion date: Jun 2026 --> Dec 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    2ms
    Natural Flavonoids Genistein and Baicalein as Well-Tolerated Radiosensitizers to Enhance the Efficacy of 177Lu-PSMA617 in Prostate Cancer: In Vitro and In Vivo Studies. (PubMed, Research (Wash D C))
    Their natural origin and established safety profile underscore their translational potential. Thus, genistein and baicalein represent promising novel adjuvants for prostate cancer radioligand therapy.
    Preclinical • Journal
    |
    CASP3 (Caspase 3)
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan)